Objective To observe the clinical efficacy of Ka-ng,ai injection combined with transcatheter arterial chem-oembolization(TACE) on Primary liver cancer(PLC). Methods 64 cases of primary liver cancer patients were randomly divided into two groups, the observation group(32 cases) received the Kang,ai injection treatment combined with TACE and the control group(32 cases) receive-ed TACE therapy only. Results The short-term efficacies of the observation group and the control group were 53.1% and 43.8%, respectively(P >0.05), with KPS improving rate 56.3% vs 31.3%(P <0.05). The occurrednce rate of adverse drug reaction such as leucopeni-a, hemoglobin decrease and liver function damage were lower in the observation group than that in the control group(P <0.05). The levels of CD3, CD4 and NK cells of the observation group increased after the treatment(P <0.05). Conclusion Kang,ai injection combined with TACE improves the life quailty of patients and decreases adverse reactions induced by TACE, at the same time, could adjust the patients,immune function.
NETL
NSTL
万方数据
维普
